ArTec, Inc. - ATKJ.PK
ArTec is the company formed to commercialize a revolutionary polysaccharide compound trade named Tubercin that has been effectively used in treatments of various cancers. ArTec, Inc., is sublicensed by Shinn Capital Group, Inc., to manufacture and distribute Tubercin in the United States and Canada . Tubercin has been granted no less than 5 issued patents both domestically and abroad, the most significant being the US patent issued August 14, 2001.
Tubercin
Tubercin is a unique immune system stimulant derived from a purified from of human tuberculosis bacteria that serves to strengthen all the elements of the human immune system and allow such elements to function together to allow the body to fight off disease. Research and Development of Tubercin is complete. The compound is fully developed and requires no further refinement or alteration in terms of its formulation. It can be effectively administered either via injectable therapy or nasal inhalation. Tubercin has been subjected to extensive animal testing in South Korea, its country of origin, as well as Human Pilot Trials involving over 500 subjects. The drug has been used for 17 years in Korea on a compassionate care basis by its originator, Dr. Chung, to treat an array of cancers, including pancreatic cancer, melanoma and colon cancer. Most instances of treatment were in patients with late stage III or IV cancer, generally deemed to be a terminal phase of the disease. Human pilot trials conducted in Korea showed no toxicity or adverse side effects, in sharp contrast to many of the standard chemotherapy protocols widely deployed by doctors worldwide today.
Objectives
Artec's goal is to establish a key strategic alliance with a major pharmaceutical entity that has a significant presence in the oncology treatment market in order to move rapidly towards US FDA approval. The Company intends to conduct new animal and initial human pilot trials in the US, in addition to those already completed in South Korea, to position itself to move through the initial Phase I clinical trials required by the FDA. The ultimate objective is to market Tubercin in both injectable and nasal delivery forms both domestically and abroad as an effective treatment for various cancers.
Mission Statement
ArTec seeks to revolutionize treatment of cancer, and ultimately, other deadly diseases by introducing, commercializing and making available Tubercin to suffering patients in the United States and Canada . The Company is committed to becoming a source of hope and relief for the myriad people across North America suffering from the scourge of cancer. Management is dedicated to making this treatment affordable for the needy.
US Patent 6,274,356
Chung, et al., August 14, 2001
Carbohydrate complex extracted from Mycobacterium tuberculosis and process for the preparation thereof
Abstract
A carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects.
tinyurl.com
Web Site: artec-inc.net
IICC Links
iicchome.com iicchome.com
For further information
Contact Mr. Gerry Knight, Executive Vice President
Ph: 405-949-1808
Email: gknight@artec-inc.net
Important postings:
IICC/Financing/New Board Member
investorshub.com |
